Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : TAVA Technologies (TAVA-NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Manzanillo who wrote (27911)	2/11/1999 5:33:00 PM
From: kfdkfd	Respond to of 31646

Note Closing BID and ASK under close. Just received a fax from TAVA on a newspaper or mag article on CSC agreement in Canada. HEADLINE: Y2K? No problem: TAVA and the Feds are takin' care of business CSC was awarded the contract and they needed TAVA expertese, so they sub contracted with TAVA since there prior experience with TAVA was good and a partnership was a natural. Comments were from CSCs project mgr.

To: Manzanillo who wrote (27911)	2/11/1999 9:41:00 PM
From: Bill Wexler	Read Replies (2) \| Respond to of 31646

<<Hey Bill, what happened with this prediction? You said last August that ZONA was going to trade below $5. It was $18 at the time, is $29 1/4 now and it hit $35 last week.>> Zona will trade below $5. The company is promoting a drug that doesn't work, but the stock gets repeatedly squeezed due to the small float and very large short position. The latest runup was due to a false report issued by one of their underwriters. When the FDA rejects Vasomax the stock will drop to the single digits in minutes. Until then, the price can be all over the map (it has traded as low as 11 and as high as 40). <<Your accusations of fraud, etc. sound very similar to what you are saying about TAVA now.>> Zonagen is fraudulently promoting their stock based on a drug that doesn't work. The drug is generic phentolamine which has been available for half a century. The Zonagen fraud relies on investor ignorance to prop up the stock price. The stock promotion fraud TAVA fraud involves misdirecting investors with the Y2K hoax. In the first case we have a wildly speculative biotech fraud, in the second, we have a tiny IT company maquerading as some sort of Y2K embedded systems powerhouse. Very different animals and both stocks also behave differently. The reason you don't see such wild price swings in TAVA is because the float has been massively diluted through converts. <<Could it be that you are wrong again?>> In both cases I am 100% correct. TAVA's stock continues to decline due to lackluster performance. In Zonagen's case, we have to wait for FDA rejection to put a final end to the fraud.